Alerta

A Method and System for Closed Loop Pulse Modulated Hormone Delivery Adapted to the Specific Half-Life Properties

Resumen de: NL1044854B1

The invention is related to a device and method for the intravenously administered administration of hormones with the aim to regulate and control, for example, a desired euglycemic homeostatic condition for individuals suffering from diabetes type 1. The hormone dose effect on the desired condition is periodically evaluated dependent on the half-life value of the administered hormone by means of measurement of the desired concentration in plasma. In this invention an intravenous method of administration of the hormone in the form of a micro bolus is used because the commonly applied method of subcutaneous administration results in an undefined and unreliable transfer of the hormone to the blood compartment which results in problems to realize an optimal unattended closed loop control system. This invention relates to a device and method using the intravenous administration of the hormones insuli n and glucagon according to their half-life properties in order to attain automatically the desired state of glucose homeostasis using continuous glucose sensors providing the electronic device with the necessary control data. The results of the proceseed data are sent, dependent on the glucose concentration, to control a here not defi lied separate insulin and glucagon pump, which administers the hormone in the form of a micao bolus. This micro bolus is always too small to cause any risk for the user. The device and method are applieable for every individual in order to control and

BLOOD SUGAR LEVEL MEASUREMENT APPARATUS AND BLOOD SUGAR LEVEL MEASUREMENT METHOD

Resumen de: WO2025216236A1

This blood sugar level measurement apparatus comprises an estimation unit that estimates blood sugar levels in a living body by using a trained machine learning model. The machine learning model is a model for outputting output data relating to a blood sugar level by inputting, as an input parameter, at least a temporal phase difference between oxygenated hemoglobin and deoxygenated hemoglobin in blood of a living body.

BLOOD GLUCOSE LEVEL MEASUREMENT DEVICE AND BLOOD GLUCOSE LEVEL MEASUREMENT METHOD

Resumen de: WO2025216237A1

This blood glucose level measurement device comprises: a light output unit that outputs light; a light detection unit that detects the light output by the light output unit and transmitted through a living body; a temporal phase difference calculation unit that calculates, on the basis of the detection result from the light detection unit, a temporal phase difference between an oxygenated hemoglobin waveform pertaining to the oxygenated hemoglobin concentration in blood of the living body and a deoxygenated hemoglobin waveform pertaining to the deoxygenated hemoglobin concentration in the blood of the living body; a blood glucose level calculation unit that calculates the blood glucose level of the living body on the basis of the calculated temporal phase difference; and a confidence level estimation unit that estimates the confidence level of the calculated temporal phase difference. The confidence level estimation unit estimates that the confidence level of the temporal phase difference is lower when the SN ratio of the detection result from the light detection unit is lower.

PEN-BASED DEVICE FOR NON-INVASIVELY CHECKING A PERSON'S BLOOD GLUCOSE CONCENTRATION

Resumen de: WO2025216649A1

The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of devices for this purpose, as well as in the creation of socially-oriented systems for the early diagnosis of diabetes and associated diseases, in the form of a pen. The aim of the invention is to improve the operational efficiency of a device for non-invasively checking a person's blood glucose concentration by reducing the set-up and configuration time required. This aim is achieved in that a device for non-invasively checking a person's blood glucose concentration is based on a pen and has a sensor disposed on one end of a housing, opposite an end containing a device for applying ink to a surface. The technical results of the invention include: obviating the need for the device to be worn on an arm; simplifying the device by the absence of a strap and by incorporation of the device into a pen; and making it possible to visually check the correct positioning of the sensor of the device on a pulse point.

ANALYTE SENSOR

Resumen de: US2025318763A1

Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.

SYSTEM AND METHOD FOR ADJUSTING INSULIN DELIVERY

Resumen de: US2025319257A1

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Some methods and systems may be configured to adjust insulin delivery to a person with diabetes according to one or more conditions of an insulin delivery device. Some methods and systems may be configured to enable a lock-out mode where adjustment to insulin delivery to personalize automated insulin delivery is restricted.

METHODS AND SYSTEMS FOR INSULIN DELIVERY AND GLUCOSE MEASUREMENT

Resumen de: US2025319256A1

In an aspect, the present disclosure provides an insulin delivery device configured to be positioned on a body of a subject via a single puncture site in said body of said subject, wherein said insulin delivery device is configured to deliver an insulin or insulin analog formulation to said subject via said single puncture site, wherein said insulin delivery device comprises a sensor configured to measure a glucose concentration in said body of said subject via said single puncture site, and wherein said delivering and said measuring are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning, while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.

DETERMINATION OF ADJUSTMENTS TO FLUID DELIVERY SETTINGS

Resumen de: US2025319254A1

Techniques disclosed herein relate to managing operations of a dual-mode insulin delivery device that can operate in a manual insulin delivery mode and an automated closed-loop insulin delivery mode. In one example, a processor-implemented method includes obtaining insulin delivery data of an insulin delivery device collected while the insulin delivery device operates in a closed-loop mode, determining an updated value of a parameter of the insulin delivery device in a manual mode based on the insulin delivery data, and causing the insulin delivery device to deliver insulin in the manual mode based on the updated value of the parameter of the insulin delivery device, where the parameter of the insulin delivery device has separate values in the manual mode and the closed-loop mode.

METHODS AND SYSTEMS FOR INSULIN DELIVERY AND GLUCOSE MEASUREMENT

Resumen de: US2025319255A1

A method may comprise (a) inserting an insulin delivery device subcutaneously into a body of a subject, which comprises an amperometric glucose sensor comprising an electrode layer comprising an indicating electrode and underlying a redox-catalytic layer comprising a redox mediator; (b) using said insulin delivery device to deliver an insulin formulation (e.g., comprising a phenol or cresol excipient) subcutaneously to said subject; and (c) using said amperometric glucose sensor to measure a subcutaneous glucose concentration, which comprises using said redox-catalytic layer to allow electron transfer from subcutaneous glucose to said indicating electrode sufficient to cause a response of said amperometric glucose sensor at an applied bias potential of no more than +250 millivolts, wherein (b) and (c) are performed at the same time for at least one hour, while maintaining a sensor sensitivity of at least 50% of an initial sensor sensitivity for up to one hour.

Implantable Glucose Sensors and Methods of Glucose Measurement Configured For Minimal Sensor Surface Obstruction

Resumen de: US2025318757A1

A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.

MINIATURIZED NONINVASIVE GLUCOSE SENSOR AND CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: US2025318759A1

Systems and methods are described herein for utilizing a photoacoustic sensor for estimating analyte concentration levels. Also described here are calibration and training methods for calibrating and/or training an analyte sensor to more accurately estimate an analyte concentration level on the basis of a received acoustic signal.

ANALYTE MONITORING SYSTEM AND METHODS

Resumen de: US2025318729A1

Disclosed embodiments include methods and systems including a receiver unit of a glucose monitoring system. The receiver unit is configured to receive a key associated with a transmitter unit that enables the receiver unit to identify the transmitter unit, initiate communication with the transmitter unit, access a communication key uniquely associated with the transmitter unit, and receive communication packets from the remote transmitter unit on a periodic basis including data indicative of a glucose level of a bodily fluid. The receiver unit is further configured to process the data determine the glucose level for display, output a numerical representation of the determined glucose level in a GUI, and transmit data indicative of the glucose level to a second receiver unit.

TECHNIQUES FOR EVALUATING IMPACTS BETWEEN PHYSIOLOGICAL DATA AND METABOLIC HEALTH

Resumen de: US2025318755A1

Methods, systems, and devices for evaluating a user's metabolic balance are described. A system may include a wearable device and a glucose monitoring device. The system may acquire physiological data from the wearable device, and blood glucose data from the glucose monitoring device. The system may be configured to determine physiological characteristics of the user based on the physiological data, such characteristics associated with a sleep quality of the user, a stress level of the user, an activity level of the user, a recovery of the user, or any combination thereof. Similarly, the system may identify metabolic characteristics of the user, such as changes in the user's blood glucose data. By overlaying and comparing the physiological data and the blood glucose data, the system may be able to evaluate how the user's physiological characteristics affect or impact the user's metabolic characteristics, or vice versa.

Low Power Implantable Glucose Sensors and Methods of Glucose Measurement

Resumen de: US2025318758A1

A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.

Methods and Systems for Measuring Glucose Having Improved Decay Rates and Lag Times

Resumen de: US2025318756A1

A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.

METHOD OF PROVIDING NOTIFICATION OF EVENT

Resumen de: AU2025200899A1

An embodiment may provide a method of providing an event notification in a glucose monitoring system, the method including determining whether an event occurs; in response to the occurrence of the event, determining whether an event occurrence time falls within a signal loss section; and outputting a notification corresponding to the event depending on whether the event occurrence time falls within the signal loss section. An embodiment may provide a method of providing an event notification in a glucose monitoring system, the method including determining whether an event occurs; in response to the occurrence of the event, determining whether an event occurrence time falls within a signal loss section; and outputting a notification corresponding to the event depending on whether the event occurrence time falls within the signal loss section. eb n e m b o d i m e n t m a y p r o v i d e a m e t h o d o f p r o v i d i n g a n e v e n t n o t i f i c a t i o n i n a e b g l u c o s e m o n i t o r i n g s y s t e m , t h e m e t h o d i n c l u d i n g d e t e r m i n i n g w h e t h e r a n e v e n t o c c u r s ; i n r e s p o n s e t o t h e o c c u r r e n c e o f t h e e v e n t , d e t e r m i n i n g w h e t h e r a n e v e n t o c c u r r e n c e t i m e f a l l s w i t h i n a s i g n a l l o s s s e c t i o n ; a n d o u t p u t t i n g a n o t i f i c a t i o n c o r r e s p o n d i n g t o t h e e v e n t d e p e n d i n g o n w h e t h e r t h e e v e n t o c c u r

PORTABLE DEVICE AND METHOD FOR NON-INVASIVE BLOOD GLUCOSE LEVEL ESTIMATION

Resumen de: AU2025237952A1

PORTABLE DEVICE AND METHOD FOR NON-INVASIVE BLOOD GLUCOSE LEVEL ESTIMATION The invention relates to a device (1) comprising a measuring unit (2) with a measuring module (4) for measuring the glucose level, a first computer module (5) for processing data from a first part of the process for measuring the glucose level, a first communications module (6), a first data storage module (7) and a pushbutton (8). The device also comprises a personal monitoring unit (3) with second and third 10 communication modules (17, 20), a second computer module (18) for processing data from a second part of the process for measuring the glucose level, an interface module (19) and a second data storage module (22). Also described is a method for non- invasive blood glucose level estimation. PORTABLE DEVICE AND METHOD FOR NON-INVASIVE BLOOD GLUCOSE LEVEL ESTIMATION The invention relates to a device (1) comprising a measuring unit (2) with a measuring module (4) for measuring the glucose level, a first computer module (5) for processing data from a first part of the process for measuring the glucose level, a first communications module (6), a first data storage module (7) and a pushbutton (8). The 10 device also comprises a personal monitoring unit (3) with second and third communication modules (17, 20), a second computer module (18) for processing data from a second part of the process for measuring the glucose level, an interface module (19) and a second data storage module (22). Also described

SYSTEMS AND METHODS FOR PROVIDING THERAPY MANAGEMENT GUIDANCE TO PATIENTS TO OPTIMIZE GLP-1 THERAPY EFFECTIVENESS

Resumen de: WO2025217339A1

Certain aspects of the present disclosure provide a monitoring system comprising one or more memories comprising executable instructions and one or more processors in data communication with the one or more memories and configured to execute the executable instructions to calculate a gastric emptying rate of a patient based on glucose measurements and lactate measurements and determine whether the gastric emptying rate of the patient is decreasing. The one or more processors are further configured to determine, if the gastric emptying rate of the patient is decreasing, whether the gastric emptying rate of the patient meets a first threshold, or whether a reduction in the gastric emptying rate over a defined period of time meets a second threshold, provide therapy management action to the patient based on the gastric emptying rate of the patient to optimize the gastric emptying rate of the patient, and recalculate, following the therapy management action, the gastric emptying rate of the patient based on the glucose measurements and the lactate measurements.

TECHNIQUES FOR EVALUATING IMPACTS BETWEEN PHYSIOLOGICAL DATA AND METABOLIC HEALTH

Resumen de: WO2025217456A1

Methods, systems, and devices for evaluating a user's metabolic balance are described. A system may include a wearable device and a glucose monitoring device. The system may acquire physiological data from the wearable device, and blood glucose data from the glucose monitoring device. The system may be configured to determine physiological characteristics of the user based on the physiological data, such characteristics associated with a sleep quality of the user, a stress level of the user, an activity level of the user, a recovery of the user, or any combination thereof. Similarly, the system may identify metabolic characteristics of the user, such as changes in the user's blood glucose data. By overlaying and comparing the physiological data and the blood glucose data, the system may be able to evaluate how the user's physiological characteristics affect or impact the user's metabolic characteristics, or vice versa.

IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MEASUREMENT DEVICE AND SYSTEM

Resumen de: WO2025216456A1

The present invention generally relates to implantable continuous blood glucose measurement technology. In particular, the present invention relates to an implantable continuous blood glucose measurement device for continuously measuring blood glucose in the body of a user, in which an oscillator for generating a variable frequency output signal corresponding to a voltage or current applied to both ends thereof is connected to a glucose fuel cell for generating electrical energy by glucose in the body, comprises an LED element, which is turned on or off by the output signal of the oscillator, or an antenna for wirelessly transmitting the output signal of the oscillator. The present invention has the advantage that blood glucose can be continuously measured in a state in which a blood glucose sensor is implanted in the body, without having to replace same.

SENSOR MEMBRANES FOR DEXAMETHOSONE REJECTION

Resumen de: EP4631428A1

Embodiments of the invention provide amperometric analyte sensors having optimized elements such as dexamethasone rejection membranes as well as methods for making and using such sensors. The amperometric analyte sensor apparatus comprises: a base layer; a conductive layer disposed on the base layer and comprising a working electrode; a dexamethasone rejection membrane disposed over an electroactive surface of the working electrode, wherein the interference rejection membrane comprises a poly Hema composition and an analyte sensing layer. While embodiments of the innovation can be used in a variety of contexts, typical embodiments of the invention include glucose sensors used in the management of diabetes.

CONTINUOUS GLUCOSE MONITORING DEVICE

Resumen de: AU2025203521A1

The present disclosure provides a continuous glucose monitoring device. The continuous glucose monitoring device comprises a body attachable unit configured to attach to a body; an applicator accommodating the body attachable unit, the applicator configured to guide the body attachable unit to be mounted on the body based on manipulation of a user; a housing comprising an inner case and an outer case; a plunger body movably disposed in the housing and configured to move from a first position to a second position along an insertion direction; a needle unit coupled to the plunger body; and a rotatable body being rotated based on a movement of the plunger body. The rotatable body is rotated when the plunger body moves from the first position to the second position. The rotatable body is positioned between the inner case and the plunger body to block movement of the plunger body in a withdrawal direction opposite to the insertion direction when the plunger body reaches the second position.

DIABETIC PUMP, APPLICATION, AND PROGRAMMING

Resumen de: WO2025212748A1

Methods and associated devices for establishing basal rates to be programmed into a diabetic pump that periodically administers insulin to a patient. The instant disclosure also includes diabetic pumps programmed in accordance with the instant disclosure.

USE OF A VARIABILITY METRIC OF GLUCOSE LEVEL VALUES TO IDENTIFY A SLEEPING TIME FRAME FOR A USER OF A MEDICAMENT DELIVERY DEVICE

Resumen de: WO2025212345A1

A variability metric of glucose level values of a user is calculated for each candidate sleeping time frame in a data set of glucose level values of the user obtained over time for a specified period for each day of multiple days. Each of the candidate sleeping time frames may represent a duration in which the user may have been sleeping. Execution of the programming instructions further may cause the processor to determine a mean or median of the variability metric of the glucose level values in the data set for each candidate sleeping time frame across the days in the specified period, designate a selected one of the candidate sleeping time frames that has the lowest mean or median variability metric as the sleeping time frame, and configure the pump to deliver a sleeping basal rate of the medicament for the designated sleeping time frame.

SYSTEM FOR PROVIDING GLUCOSE MANAGEMENT SERVICE AND METHOD FOR RECOMMENDING CONTINUOUS GLUCOSE MONITORING

Nº publicación: WO2025211546A1 09/10/2025

Solicitante:

KAKAO HEALTHCARE CORP [KR]
\uC8FC\uC2DD\uD68C\uC0AC \uCE74\uCE74\uC624\uD5EC\uC2A4\uCF00\uC5B4